Trailing-twelve-month (TTM) revenue is $2.91 Billion with a year-over-year growth of +4.05%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-28 | $698,949,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-28 | $772,056,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-04-05 | $711,118,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-07-05 | $729,688,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $2,911,811,000 |
Current P/S: $16,464,024,800 market capitalization ÷ $2,911,811,000 TTM revenue = 5.65x.
Market capitalization source: FMP quote. Quote observed 2026-09-17T19:50:12.000Z. Latest revenue period ended 2026-07-05.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-07-05): $729.69M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-17T19:51:07.455Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|
| Diagnostics | $1.5B | $1.4B |
| Life Sciences | $1.3B | $1.4B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|
| CHINA | $450M | $425M |
| GERMANY | N/A | $178M |
| Other International | $2.8B | $2.7B |
| UNITED KINGDOM | $113M | $127M |
| UNITED STATES | $1.1B | $1.1B |
$2.91B
$2.91 Billion
+4.05%
vs. $2.80B a year ago (TTM)
(9.69%)
5 Year compound annual growth rate
1 Year
+4.05%
3 Year
+0.87%
5 Year
(9.69%)
10 Year
+2.46%
15 Year
+3.19%
20 Year
+3.45%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.86B | +$101.03M | +3.67% |
| 2024 | $2.76B | +$4.46M | +0.16% |
| 2023 | $2.75B | ($561.25M) | (16.95%) |
| 2022 | $3.31B | ($515.99M) | (13.48%) |
| 2021 | $3.83B | +$45.06M | +1.19% |
| 2020 |
TTM Growth
+4.05%
3-Year CAGR
+0.87%
5-Year CAGR
(9.69%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-17T19:51:07.455Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $3.78B |
| +$899.07M |
| +31.18% |
| 2019 | $2.88B | +$105.68M | +3.80% |
| 2018 | $2.78B | +$521.01M | +23.08% |
| 2017 | $2.26B | +$141.47M | +6.69% |
| 2016 | $2.12B | +$10.69M | +0.51% |
